; (B) is subject to section 503(b)(1) of such Act ( 21 U.S.C. 353(b)(1) ); and (C) is covered by a qualifying patent on the drug, on a method of using such drug, or on a method or machine used to manufacture or administer such drug with respect to which the drug sponsor retained the title to any subject invention under section 202 of title 35, United States Code, or entered into a licensing agreement after the date of enactment of this Act. (2) Conflict of interest The term conflict of interest means an association, including a financial or personal association, or past employment, that has the potential to bias or have the appearance of biasing an individual’s decisions in matters related to the Drug Affordability and Access Committee or the conduct of other activities under this Act. (3) Manufacturer list price The term manufacturer list price means the national price for a prescription drug established by the manufacturer or licensee found in a catalogue or other public source that is the price from which market discounts and price concessions are calculated. (4) Period of market exclusivity The term period of market exclusivity means any period of market exclusivity granted with respect to a prescription drug under clause (ii), (iii), or (iv) of section 505(c)(3)(E) of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 355(c)(3)(E) ), clause (ii), (iii), or (iv) of section 505(j)(5)(F) of such Act, section 527 of such Act ( 21 U.S.C. 360cc ), or section 351(k)(7) of the Public Health Service Act ( 42 U.S.C. 262(k)(7) ), and any extension of such period granted under section 505A or 505E of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 355a , 355f). (5) Qualifying patent The term qualifying patent means any patent— (A) held by the Federal Government